OpenAlex 3.500 eser 87 yazar konusu
Çalışmalar
3.500 eser
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III,…
Akademisyenler
87 akademisyen
- HAKKI KAYA 31 yazar konusu
- MEHDİ ZOGHİ 27 yazar konusu
- NURAY ENÇ 14 yazar konusu
- CANAN BAYDEMİR 11 yazar konusu
- İBRAHİM AKIN 11 yazar konusu
- ONUR ARGAN 11 yazar konusu
- EMRE DEMİR 10 yazar konusu
- FEZAN MUTLU 10 yazar konusu
- TANER ŞEN 9 yazar konusu
- İSMAİL TÜRKAY ÖZCAN 8 yazar konusu
- MUSTAFA KARABACAK 8 yazar konusu
- MUSTAFA YENERÇAĞ 8 yazar konusu